GeneralTop StoryTop StoryLatest News
Personalised mRNA Cancer Vaccine Shows Dramatic Reduction in Death Risk
Sentiment: PositiveHigh Priority
What Happened?
A personalised cancer vaccine by Merck and Moderna has shown significant improvements in melanoma outcomes when combined with Keytruda, reducing recurrence and metastasis risks. The findings were presented at the ESMO Congress.
Key points
- The Phase 3 INTerpath-001 trial involved 1,137 patients with high-risk melanoma.
- The combination of the vaccine and Keytruda reduced the risk of melanoma recurrence or death by 42%.
- After 24.6 months, 82.2% of patients receiving the combination were alive without recurrence.
- The vaccine uses synthetic mRNA to target up to 34 tumour-specific neoantigens.
- Treatment-related adverse events were reported in 95.8% of patients receiving the combination.
Key insights
- The success of this vaccine could pave the way for mRNA technology in treating various cancers.
- Personalised vaccines may change the approach to cancer treatment by focusing on individual tumour mutations.
- The findings highlight the potential of combining different treatment modalities for better outcomes.
Why it matters
This development could lead to more effective cancer treatments tailored to individual patients.
Entities
Merck· CompanyModerna· CompanyKeytruda· Productmelanoma· DiseaseEuropean Society for Medical Oncology· OrganizationAll India Institute of Medical Sciences· Organization
Source
India Today
